Answers are grounded in this paper and cite their sources.
Neuroinflammation and blood–brain barrier (BBB) dysfunction are two interconnected pathways that are involved in acute cerebrovascular injury, demyelinating disease, epilepsy, and neurodegeneration. One of the current obstacles is to identify the alteration of the barrier before it becomes evident by traditional imaging methods such as leakage, edema, or tissue injury. Dynamic contrast-enhanced MRI (DCE-MRI) measures BBB permeability to gadolinium-based agents; arterial spin labeling (ASL) and water exchange techniques assess BBB trans endothelial water transport; positron emission tomography (PET) maps inflammatory cell targets of the BBB or specific transport processes; and diffusion/perfusion measures provide contextual information on microvascular and tissue consequences. This narrative review aimed to present the provided references and methodological literature collecting them together with a focus on the biological interpretation, the strengths, and the limitations. These techniques are shown to be promising research biomarkers but are not universally validated as early diagnostic tests. For clinical translation, harmonized acquisition, modeling, longitudinal analysis and careful separation from the vascular confounding variables are prerequisites.
No takes yet. Share an insight, caveat, or question.
Mozafari et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: